{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:13:10Z","timestamp":1783041190635,"version":"3.54.6"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Phosphodiesterase type 5 (PDE5) inhibitors are the first line drugs for treatment of erectile dysfunction. Sildenafil (ViagraR), tadalafil (CialisR), and vardenafil (LevitraR) are from the same class of drugs that inhibit PDE5. Transient visual symptoms such as change in color perception and increased light sensitivity are well-known adverse effects of these drugs and occur in 3\u201311% of sildenafil users. Vision-threatening (serious) ocular complications, such as nonarteritic ischemic optic neuropathy and cilio-retinal artery occlusion have rarely been reported in PDE5 inhibitor users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To highlight and analyze the most recently published case literature on serious ocular complications of PDE5 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Search of the peer-reviewed English literature was conducted using Medline. The following databases also were searched: Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Global Health, and MD Consult. The causality assessment of the reported adverse drug reactions was analyzed by applying both the World Health Organization (WHO) Probability Scale and the criteria utilized by the National Registry of Drug-Induced Ocular Side Effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>To scientifically and objectively find out if PDE5 inhibitors are associated with vision-threatening ocular complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight case reports of serious PDE5 inhibitor-associated ocular complications were identified since January 2006 until February 2011. Case reports included cases of anterior and posterior nonarteritic ischemic optic neuropathy, central retinal vein occlusion, cilio-retinal artery occlusion, acute angle closure glaucoma and optic atrophy after sildenafil use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is lack of conclusive evidence to indicate a direct cause\u2013effect relationship between PDE5 inhibitor use and vision-threatening ocular events. Men who use PDE5 inhibitors appear to suffer vision-threatening complications at the same frequency as the general population. However, minor visual adverse effects occur in 3\u201311% of users and they are transient and reversible.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1743-6109.2011.02382.x","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T23:11:47Z","timestamp":1311117107000},"page":"2894-2903","source":"Crossref","is-referenced-by-count":68,"title":["Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature"],"prefix":"10.1093","volume":"8","author":[{"given":"F.","family":"Azzouni","sequence":"first","affiliation":[{"name":"Department of Urology \u00a0 , Buffalo, NY , USA"},{"name":"Roswell Park Cancer Institute \u00a0 , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Abu samra","sequence":"additional","affiliation":[{"name":"The State University of New York \u00a0 \u00a0 , Buffalo, NY , USA"},{"name":"University at Buffalo \u00a0 \u00a0 , Buffalo, NY , USA"},{"name":"Ross Eye Institute \u00a0 \u00a0 , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"2023012309033300600_bb0010","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-005-4533-5","article-title":"Phosphodiesterase: Overview of protein structures, potential therapeutic applications, and recent progress in drug development","volume":"62","author":"Jeon","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"2023012309033300600_bb0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"2023012309033300600_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jns.2007.06.018","article-title":"Anterior ischemic optic neuropathy and stoke with use of PDE-5 inhibitors for erectile dysfunction: Cause or coincidence?","volume":"262","author":"Carter","year":"2007","journal-title":"J Neurol Sci"},{"key":"2023012309033300600_bb0025","article-title":"IMS commissioned report and 2.7.4 summary of clinical safety. Data on file","year":"2008"},{"key":"2023012309033300600_bb0030","first-page":"820","article-title":"Erectile dysfunction. New drugs with special consideration of the PDE5 inhibitors","volume":"43","author":"Porst","year":"2004","journal-title":"Urologe A"},{"key":"2023012309033300600_bb0035","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/01.RES.0000056757.93432.8C","article-title":"Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat","volume":"92","author":"Zhang","year":"2003","journal-title":"Circ Res"},{"key":"2023012309033300600_bb0040","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"2023012309033300600_bb0045","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/j.1743-6109.2009.01447.x","article-title":"2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class","volume":"6","author":"Shindel","year":"2009","journal-title":"J Sex Med"},{"key":"2023012309033300600_bb0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.vph.2006.01.013","article-title":"A potential role for sildenafil in the management of pulmonary hypertension in patients with parynchymal lung disease","volume":"44","author":"Madden","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"2023012309033300600_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijcard.2010.10.121","article-title":"Effects of sildenafil in combination with angiotensin-converting enzyme inhibitor on limiting infarct expansion in a porcine model of acute myocardial infarction","volume":"146","author":"Sim","year":"2011","journal-title":"Int J Cardiol"},{"key":"2023012309033300600_bb0060","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1152\/ajpheart.00100.2009","article-title":"ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice","volume":"296","author":"Das","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023012309033300600_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-445X.2000.01966.x","article-title":"Visual signals in the retina: From photons to synapses","volume":"85","author":"Lagando","year":"2000","journal-title":"Exp Physiol"},{"key":"2023012309033300600_bb0070","first-page":"177","article-title":"Study 148-232: A randomised, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral tablet dose of sildenafil (200\u2003mg) on visual function (electroretinogram, photostress, visual field and colour discrimination tests) in healthy male volunteers and patients with diabetic retinopathy","year":"1998"},{"key":"2023012309033300600_bb0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ajo.2003.11.081","article-title":"Visual short term effects of Viagra: Double blind study in healthy young subjects","volume":"44","author":"Jagel","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"2023012309033300600_bb0080","article-title":"Full prescribing information sildenafil citrate","year":"2008"},{"key":"2023012309033300600_bb0085","article-title":"Full prescribing information vardenafil","year":"2008"},{"key":"2023012309033300600_bb0090","article-title":"Full prescribing information tadalafil","year":"2008"},{"key":"2023012309033300600_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00041327-200103000-00006","article-title":"Anterior ischemic optic neuropathy associated with Viagra","volume":"21","author":"Cunnigham","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","article-title":"Ocular adverse effects associated with systemic medications: Recognition and management","volume":"67","author":"Santealla","year":"2007","journal-title":"Drugs"},{"key":"2023012309033300600_bb0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2023012309033300600_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.ijir.3901544","article-title":"Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care","volume":"19","author":"Kim","year":"2007","journal-title":"Int J Impot Res"},{"key":"2023012309033300600_bb0115","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"2023012309033300600_bb0120","first-page":"3233","article-title":"Non-artertic ischemic optic neuropathy and phosphodiesterase type 5 inhibitors","volume":"13","author":"Bella","year":"2006","journal-title":"Can J Urol"},{"key":"2023012309033300600_bb0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/ijir.2008.25","article-title":"Non-artertic ischemic optic neuropathy with PDE5 inhibitors for erectile dysfunction","volume":"20","author":"Thurtell","year":"2008","journal-title":"Int J Impot Res"},{"key":"2023012309033300600_bb0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1368-5031.2006.00904.x","article-title":"Sildenafil citrate use and the incidence of nonarteritic ischemic optic neuropathy","volume":"60","author":"Gorkin","year":"2006","journal-title":"Int J Clin Pract"},{"key":"2023012309033300600_bb0135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archopht.123.3.400","article-title":"Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallange","volume":"123","author":"Bollinger","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"2023012309033300600_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00041327-199403000-00011","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population based study in the state of Missuri and Los Angeles county. California","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.wno.0000205622.45263.ad","article-title":"Non arteritic anterior ischemic optic neuropathy, erectile dysfunction drugs, and amiodaron: Is there a relationship?","volume":"26","author":"Fraunfelder","year":"2006","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/mol.104.001388","article-title":"Cyclic GMP and phosphodiesterase 5 inhibitors therapies: What's on the horizon?","volume":"66","author":"Lincolin","year":"2004","journal-title":"Mol Pharmacol"},{"key":"2023012309033300600_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0039-6257(99)00079-X","article-title":"Sildenafil and ophthalmology","volume":"44","author":"Marmor","year":"1999","journal-title":"Surv Ophthalmol"},{"key":"2023012309033300600_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041327-200503000-00003","article-title":"Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil: A report of seven new cases","volume":"25","author":"Pomeranz","year":"2005","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/jop.2005.21.315","article-title":"Case report: Association of combined nonareteritic ischemic optic neuropathy and obstruction of cilioretinal artery with overdose of Viagra","volume":"21","author":"Akash","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"2023012309033300600_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9394(98)00243-8","article-title":"Pupil sparing third nerve palsy associated with sildenafil citrate","volume":"126","author":"Donahue","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"2023012309033300600_bb0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOU.0b013e328333ac68","article-title":"Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia","volume":"20","author":"Wang","year":"2010","journal-title":"Curr Opin Urol"},{"key":"2023012309033300600_bb0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.crd.0000233904.77128.49","article-title":"Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease","volume":"15","author":"Ravipati","year":"2007","journal-title":"Cardiol Rev"},{"key":"2023012309033300600_bb0185","article-title":"Viagra (Sildenafil citrate)","author":"FDA","year":"2006"},{"key":"2023012309033300600_bb0190","first-page":"249","article-title":"Central retinal vein occlusion in a patient after being commenced on Sildenafil citrate for pulmonary arterial hypertension","volume":"51","author":"Pinto","year":"2009","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"2023012309033300600_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1439-0272.2009.00933.x","article-title":"Non-arteritic ischemic optic neuropathy after 36 hours of intake of sildenafil citrate: First Egyptian case","volume":"41","author":"El-Domyati","year":"2009","journal-title":"Andrologia"},{"key":"2023012309033300600_bb0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/WNO.0b013e31816743da","article-title":"Stepwise decline in visual field after serial sildenafil use","volume":"28","author":"Pepin","year":"2008","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/WNO.0b013e318167554a","article-title":"Bilateral posterior ischemic optic neuropathy associated with use of sildenafil","volume":"28","author":"Hsien-wen","year":"2008","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pediatrneurol.2007.06.023","article-title":"Ischemic optic neuropathy in a child","volume":"37","author":"Sivaswamy","year":"2007","journal-title":"Pediatr Neurol"},{"key":"2023012309033300600_bb0215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.optm.2007.01.005","article-title":"Optic atrophy after sildenafil use","volume":"78","author":"Sowka","year":"2007","journal-title":"Optometry"},{"key":"2023012309033300600_bb0220","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.eye.6702445","article-title":"Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient","volume":"21","author":"Gedik","year":"2007","journal-title":"Eye"},{"key":"2023012309033300600_bb0225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0420.2006.00803.x","article-title":"Acute angle closure glaucoma following sildenafil citrate- aided sexual intercourse","volume":"85","author":"Ramasamy","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"2023012309033300600_bb0230","article-title":"Letter MIO\/372\/2(A)","year":"1991"},{"key":"2023012309033300600_bb0235","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/BF03349261","article-title":"The use of phosphodiesterase 5 inhibitors with concomitant medications","volume":"31","author":"Corona","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2023012309033300600_bb0240","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/S0149-2918(03)80329-6","article-title":"Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of European multicenter, open-label study of patient preference","volume":"25","author":"Stroberg","year":"2003","journal-title":"Clin Ther"},{"key":"2023012309033300600_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic ischemic optic neuropathy","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"2023012309033300600_bb0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/eye.1990.4","article-title":"Anterior ischemic optic neuropathy: Differentiation of arteritic from nonarteritic type and its management","volume":"4","author":"Hayresh","year":"1990","journal-title":"Eye"},{"key":"2023012309033300600_bb0255","first-page":"1366","article-title":"Characterestic of patients with nonarteritic anterior ischemic optic neuropathy eligible for the ischemic optic neuropathy decompression trial","volume-title":"Arch Ophthalmol","author":"Ischemic Optic Neuropathy Decompression Trial Research Group","year":"1996"},{"key":"2023012309033300600_bb0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","article-title":"Pathogenesis of nonarteritic anterior ischemic optic neuropathy","volume":"23","author":"Arnold","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"2023012309033300600_bb0265","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0002-9394(14)73478-6","article-title":"Optic disc risk factors for nonarteritic anterior ischemic optic neuropathy","volume":"116","author":"Burd","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"2023012309033300600_bb0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00019052-200402000-00006","article-title":"Ischemic optic neuropathies","volume":"17","author":"Rucker","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"2023012309033300600_bb0275","article-title":"Sildenafil citrate (marketed as Viagra) Information for Healthcare Professionals, year","author":"FDA","year":"2005"},{"key":"2023012309033300600_bb0280","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2009.02254.x","article-title":"Safety of sildenafil citrate: Review of 67 double-blind placebo controlled trials and the postmarketing safety database","volume":"64","author":"Giuliano","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2023012309033300600_bb0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000027399","article-title":"Role of nocturnal arterial hypotension in optic nerve head ischemic disorders","volume":"213","author":"Hayerh","year":"1999","journal-title":"Ophthalmologica"},{"key":"2023012309033300600_bb0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9149(99)00046-6","article-title":"Overall cardiovascular profile of sildenafil citrate","volume":"83","author":"Zusman","year":"1999","journal-title":"Am J Cardiol"},{"key":"2023012309033300600_bb0295","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1212\/WNL.57.9.1730","article-title":"Transient ischemic attack and stroke associated with sildenafil use","volume":"57","author":"Morgan","year":"2001","journal-title":"Neurology"},{"key":"2023012309033300600_bb0300","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1167\/iovs.09-4862","article-title":"Effect of sildenafil and tadalafil on intraocular pressure in sheep: Implication for aqueous humor dynamics","volume":"51","author":"Gerometta","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023012309033300600_bb0305","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9394(00)00375-5","article-title":"No clinically important effects on intraocular pressure after short term administration of sildenafil citrate","volume":"129","author":"Yajima","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"2023012309033300600_bb0310","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bjo.2007.131789","article-title":"The effect of Sildenafil on ocular blood flow","volume":"92","author":"Harris","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"2023012309033300600_bb0315","author":"FDA alert (07\/2005) for health care professionals, Sildenafil citrate (viagra) FDA."},{"key":"2023012309033300600_bb0320","article-title":"FDA updates labeling for Viagra, cialis and levitra for rare postmarketing reports of eye problems","author":"FDA","year":"2005"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515332896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515332896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/10\/2894\/48607066\/jsm_8_10_2894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/10\/2894\/48607066\/jsm_8_10_2894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T21:46:01Z","timestamp":1712612761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/8\/10\/2894\/6980061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,1]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02382.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,10]]},"published":{"date-parts":[[2011,10,1]]}}}